Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
9.12 CNY +2.36% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. +1.56% -6.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets MT
Shyndec Pharma Passes Drug GMP Compliance Inspection MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection MT
Shanghai Shyndec Pharma Chairman Resigns MT
Shyndec Pharmaceutical Unit's Infection Drug Passes Regulatory Evaluation MT
Shyndec Pharma Unit's Clindamycin Phosphate Injection Passes Regulatory Evaluation MT
Amoxicillin Capsules of Shyndec Pharma's Unit Passes Regulatory Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shyndec Pharma Unit Acquires Marketing Rights of Ceftazidime Avibactam Sodium for 22 Million Yuan; Shares Jump 9% MT
Suning.com Promotes Former IT Head to Chairman, President MT
Shyndec Pharma Unit's Antibiotic Passes Drug Regulator's Evaluation MT
Shyndec Pharma Unit's Anti-Bacterial Drug Passes Regulator's Consistency Evaluation MT
Shyndec Pharma Unit's Anti-Infection Drug Gets Regulatory Approval MT
Shyndec Pharma Logs 10.3% Rise in FY'22 Profit; Shares Rose 3% MT
Chart Shanghai Shyndec Pharmaceutical Co., Ltd.
More charts
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.
Calendar
More about the company
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW